NEU neuren pharmaceuticals limited

Neuren Media and Analyst Coverage, page-1447

  1. 1,409 Posts.
    lightbulb Created with Sketch. 651
    Eagle - I hope this makes sense.

    Did you interpret his comments of 4-5 x Trofinetide deal, to be 4-5x the value of the Acadia deal OR did you think he meant 4-5x the value of Trofinetide as a product, which you could argue (and JP has stated) has a good comparative value in Skyclaris (Reata).

    Sorry if that distinction is not clear.Just curious as to how others interpreted the comment. I admit my initial thoughts were the former valuation but then on further thought came to the conclusion that it does not make sense, when you consider his references to Reata for a single indication.
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
$16.48
Change
-0.290(1.73%)
Mkt cap ! $2.076B
Open High Low Value Volume
$16.58 $16.74 $16.40 $9.107M 549.9K

Buyers (Bids)

No. Vol. Price($)
1 864 $16.43
 

Sellers (Offers)

Price($) Vol. No.
$16.50 1668 1
View Market Depth
Last trade - 16.10pm 25/07/2025 (20 minute delay) ?
NEU (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.